Emergen Research has released its latest Global Preimplantation Genetic Testing Market Report, offering a detailed and well-structured analysis of the industry to help businesses, investors, and stakeholders understand evolving market conditions. The study provides a forward-looking perspective on the Preimplantation Genetic Testing market, covering the forecast period from 2024 to 2033 while incorporating historical insights to present a complete picture of market performance.
The preimplantation genetic testing market is expected to grow from an estimated USD 0.8 billion in 2024 to USD 2.2 billion in 2033, at a CAGR of 11.90%.
The global preimplantation genetic testing market size is expected to grow from 0.8 billion by the end of 2024 to 2.2 billion by 2033, registering a revenue CAGR of 11.90% during the forecast period. Preimplantation genetic testing (PGT) is gaining significant attention within the global assisted reproductive technologies (ART) industry.
The advancement in PGT methods is driving better outcomes for families experiencing infertility, as it allows the identification of genetic conditions in embryos prior to implantation. According to the American Society for Reproductive Medicine (ASRM), the prevalence of genetic disorders, including aneuploidy and single gene disorders, has spurred the growth of the PGT market. Additionally, PGT procedures enable the selection of healthy embryos for implantation, which enhances pregnancy rates and reduces the risk of genetic diseases.
Furthermore, the increasing use of advanced technologies like next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH) is contributing to the robust market growth. The market is further being propelled by rising awareness of genetic screening among patients and the availability of improved treatment options through fertility clinics and diagnostic laboratories.
Market trends indicate a growing preference for non-invasive methods and improved genetic testing solutions. For instance, a report by the International Society for Prenatal Diagnosis (ISPD) noted that over 15 million genetic testing procedures were conducted globally in 2023, showcasing the expanding need for genetic screening in reproductive health. This market expansion is also supported by technological innovations, such as single-nucleotide polymorphism (SNP) testing and advances in genomic analysis, which allow for more precise and reliable genetic profiling.
The report is designed to deliver not only statistical data but also meaningful insights that support strategic decision-making. By combining qualitative observations with quantitative analysis, the study ensures that businesses can clearly interpret market trends and apply them effectively. It also addresses key questions such as identifying leading market participants, understanding changing consumer demand, and evaluating the strategies adopted by companies to strengthen their presence in the Preimplantation Genetic Testing market.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4006
Market Segmentation:-
An important aspect of this research is its focus on supply-demand dynamics and production-consumption patterns. The report carefully examines how these elements influence pricing, availability, and overall market performance. It also includes insights into cost-benefit considerations, technological developments, and operational strategies, which play a significant role in shaping the growth of the Preimplantation Genetic Testing market.
The preimplantation genetic testing market is having high competition, with several key players offering a wide range of services and technological advancements. Major players include Illumina, Inc., Thermo Fisher Scientific, LabCorp, and PGT Healthcare, which lead the market with cutting-edge genetic testing solutions for preimplantation diagnostics and screening. These companies focus on expanding their product portfolios through strategic acquisitions, partnerships, and technological innovations to stay ahead in the market.
For instance, in January 2024, Illumina announced a collaboration with Genomics England to advance preimplantation genetic testing methods, aiming to improve genetic screening accuracy and enhance IVF success rates. Such collaborations are expected to drive growth and solidify market leadership for these companies in the coming years.
Some of the key companies in the global Preimplantation Genetic Testing Market include:
- Ferring Pharmaceuticals
- Illumina, Inc.
- Genomic Health, Inc.
- Invitae Corporation
- Thermo Fisher Scientific
- Agilent Technologies, Inc.
- Genesis Genetics
- CooperSurgical, Inc.
- Prevention Genetics
- Reproductive Medicine Associates (RMA)
The segmentation analysis provides a deeper understanding of how the market is structured across different categories. By dividing the Preimplantation Genetic Testing market into specific segments based on product types, applications, and end-use industries, the report allows businesses to identify areas with the highest growth potential. This approach helps organizations refine their strategies and focus on segments that align with their objectives.
Competitive landscape:-
Another significant component of the report is its detailed competitive landscape analysis. The study provides an overview of major companies operating in the market and evaluates their business models, product offerings, and pricing strategies. It also highlights key developments such as mergers and acquisitions, collaborations, joint ventures, and product innovations that have influenced the competitive environment.
Growing Demand for Genetic Screening in Reproductive Health
The increasing demand for preimplantation genetic testing (PGT) is driven by growing awareness among patients and healthcare professionals regarding genetic diseases and their impact on reproductive outcomes. The rise in infertility rates, particularly in developed countries, is contributing to a heightened focus on genetic screening procedures.
According to the Centers for Disease Control and Prevention (CDC), approximately 12% of women in the United States aged 15-44 years have difficulty conceiving or carrying a pregnancy to term, highlighting the need for assisted reproductive technologies (ART) such as PGT. Furthermore, the increasing prevalence of genetic disorders, including aneuploidy, single-gene disorders, and structural chromosomal abnormalities, is prompting more families to seek genetic testing solutions during their fertility treatments.
As a result, fertility clinics and hospitals are adopting advanced genetic testing methods to ensure better outcomes for patients. The demand for PGT is also being supported by improved clinical outcomes, as PGT helps in identifying embryos without genetic abnormalities, thereby improving the chances of successful pregnancies.
In addition, advancements in genomic technologies, such as next-generation sequencing (NGS), have enhanced the accuracy and efficiency of genetic testing, further driving market growth. The integration of artificial intelligence (AI) and machine learning (ML) technologies in PGT platforms is expected to revolutionize the market by providing more accurate predictions of genetic disorders.
For instance, in September 2023, Invitae Corporation, a leader in genetic testing, launched a new PGT service that utilizes AI-driven algorithms to predict chromosomal abnormalities with higher accuracy, thereby increasing the success rates of assisted reproductive treatments.
In addition to company profiling, the report incorporates analytical tools such as industry analysis frameworks to provide a deeper understanding of competition and market positioning. These insights help businesses evaluate their strengths and weaknesses while identifying opportunities for differentiation.
The impact of external disruptions is also thoroughly examined in the report. The COVID-19 pandemic, for instance, has had a notable effect on the Preimplantation Genetic Testing market, influencing both demand and supply chains. The study outlines how lockdowns, movement restrictions, and economic slowdowns have impacted industry growth. It further explores how companies have adapted to these challenges by modifying their strategies and adopting new operational approaches.
Beyond identifying growth drivers, the report also discusses restraining factors that may affect the market. By presenting a balanced analysis, Emergen Research enables businesses to prepare for uncertainties and develop resilient strategies. This includes evaluating risks associated with pricing volatility, raw material sourcing, and changes in consumer behavior.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/preimplantation-genetic-testing-market
Another valuable feature of the report is its focus on innovation and technological advancements. It highlights the importance of research and development activities in driving market growth and improving product quality. Companies that invest in innovation are better positioned to maintain a competitive edge and respond to evolving market demands.
The report also includes insights into strategic planning and expansion opportunities. It provides guidance on how businesses can strengthen their market presence, enter new segments, and optimize their operations. These recommendations are particularly beneficial for new entrants as well as established players seeking to expand their footprint.
Emergen Research ensures that its findings remain relevant by continuously updating its research based on the latest market developments. This commitment to accuracy and timeliness makes the report a reliable source of information for businesses operating in dynamic environments.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4006
In conclusion, the Global Preimplantation Genetic Testing Market Report offers a comprehensive understanding of industry trends, competitive dynamics, and growth opportunities. Its combination of detailed analysis, accurate forecasting, and actionable insights makes it an essential tool for organizations aiming to achieve sustainable growth and long-term success.
About Emergen Research
Emergen Research is a leading market research and consulting firm that specializes in providing syndicated reports, customized research solutions, and strategic advisory services. The company focuses on delivering fact-based insights and helping businesses understand market trends, analyze consumer behavior, and make informed decisions in a competitive global landscape.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com